RxDoctor Payments Data

Arthi Reddy, MD

Internal Medicine · New York, NYNPI 1760663363

Payments from drug & device makers

$1,689in general payments, 2019–2025

Across 60 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$308
  • Genentech USA, Inc.$240
  • E.r. Squibb & Sons, L.L.C.$226
  • Lilly USA, LLC$145
  • Boehringer Ingelheim$139
  • Pfizer$118
  • plus $513 from 10 others

What the payments were for

  • Food & beverage$1,689100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,689 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$154,081
Medicare patients
352
Services billed
1,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$60,226
JardianceEmpagliflozin43$54,820
OzempicSemaglutide27$31,587
MounjaroTirzepatide18$20,622
XareltoRivaroxaban15$18,033
MyrbetriqMirabegron12$15,954
EntrestoSacubitril/Valsartan14$13,176
JanuviaSitagliptin Phosphate14$12,700
Atorvastatin Calcium634$6,150
Arnuity ElliptaFluticasone Furoate27$5,481
Wixela InhubFluticasone Propion/Salmeterol15$3,472
DexilantDexlansoprazole11$3,250
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,763
Levothyroxine Sodium189$2,496
Dexlansoprazole DrDexlansoprazole12$2,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$60,22653 claims
Boehringer IngelheimJardiance$139$54,82043 claims
Novo NordiskOzempic$87$31,58727 claims
Lilly USA, LLCMounjaro$145$20,62218 claims
Johnson & JohnsonXarelto$87$18,03315 claims
MerckJanuvia$99$12,70014 claims
AbbVieSynthroid$44$2,13441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →